Palisade Bio Earnings Call Transcripts
Fiscal Year 2026
-
A novel oral PDE4 inhibitor prodrug for IBD showed strong early efficacy and safety in UC and Crohn's, with 100% response in a UC phase Ib and robust PK/PD in Crohn's. Phase II trials are set for 2024, supported by $135M in cash and a precision medicine approach.
-
Phase I-B data for PALI-2108 in fibrostenotic Crohn's disease showed strong safety, robust PK/PD, and early clinical activity, with 40% endoscopic response/remission in a refractory population. Once-daily oral dosing and dual anti-inflammatory/anti-fibrotic action support further development in broader Crohn's cohorts.
-
PALI-2108, a locally activated PDE4 inhibitor prodrug, is advancing in IBD with strong early efficacy and safety data, a dual anti-inflammatory/anti-fibrotic mechanism, and a robust financial runway. Key clinical milestones are set for 2024–2028, with strategic flexibility in Crohn's indications.
-
The company has restructured around a novel, gut-restricted PDE4 inhibitor with promising early clinical results in UC and FSCD. With strong financial backing and a clear development timeline, it is positioned for expansion into broader GI and potential non-GI indications.
Fiscal Year 2025
-
Upcoming milestones include early 2025 data from a Phase 1b Crohn's study and a definitive Phase II UC trial, both supported by strong fundraising. The lead PDE4 inhibitor shows rapid, potent efficacy with a favorable safety profile, targeting high unmet needs in IBD.
-
PALI-2108, a novel oral PDE4 inhibitor prodrug, shows strong safety and targeted delivery for ulcerative colitis, with promising Phase I results and potential application in Crohn's disease. The IBD market is lucrative, and further updates on development are anticipated.
Fiscal Year 2024
-
The event highlighted a novel PDE4 inhibitor for ulcerative colitis, with a precision medicine approach and strong preclinical data. The company is preparing for phase I trials, targeting a large market, and has received positive feedback from pharma partners.
-
The session highlighted a novel PDE4 inhibitor for ulcerative colitis, featuring a pro-drug formulation designed to improve efficacy and tolerability. Human trials are set to begin soon, with a precision medicine approach and strong management investment backing the program.